(Q31145317)

29 June 2017

A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design (English)

1 reference

29 June 2017

13

Joseph Schlessinger

1 reference

29 June 2017

12

Sung-Hou Kim

1 reference

29 June 2017

10

Gideon Bollag

1 reference

29 June 2017

4

Chao Zhang

1 reference

29 June 2017

6

Sam Gillette

1 reference

29 June 2017

14

Kam Y J Zhang

1 reference

29 June 2017

8

Prabha N Ibrahim

1 reference

29 June 2017

9

Dean R Artis

1 reference

29 June 2017

1

Graeme L Card

1 reference

29 June 2017

Landy Blasdel

2

1 reference

29 June 2017

Bruce P England

3

1 reference

29 June 2017

Yoshihisa Suzuki

5

1 reference

29 June 2017

Daniel Fong

7

1 reference

29 June 2017

Michael V Milburn

11

1 reference

29 June 2017

30 January 2005

1 reference

29 June 2017

1 reference

29 June 2017

23

1 reference

29 June 2017

201-207

1 reference

29 June 2017

2

1 reference

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

29 June 2017

1 reference

Fragment-Based Drug Discovery

21 January 2018

1 reference

Fragment-based lead discovery

21 January 2018

1 reference

Discovering high-affinity ligands for proteins: SAR by NMR

21 January 2018

1 reference

Discovering novel ligands for macromolecules using X-ray crystallographic screening

21 January 2018

1 reference

Tethering: fragment-based drug discovery

21 January 2018

1 reference

Phosphodiesterase 5 inhibitors: current status and potential applications

21 January 2018

1 reference

Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors

21 January 2018

1 reference

Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling.

21 January 2018

1 reference

Cyclic nucleotide research -- still expanding after half a century

21 January 2018

1 reference

Phosphodiesterases and cyclic nucleotide signaling in endocrine cells

21 January 2018

1 reference

Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling.

21 January 2018

1 reference

PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization

21 January 2018

1 reference

Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses

21 January 2018

1 reference

Structural basis for the activity of drugs that inhibit phosphodiesterases

21 January 2018

1 reference

A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases

21 January 2018

1 reference

A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules

21 January 2018

1 reference

From The Cover: Automated protein crystal structure determination using ELVES

21 January 2018

1 reference

Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity

21 January 2018

1 reference

Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity

21 January 2018

1 reference

Improved methods for building protein models in electron density maps and the location of errors in these models

21 January 2018

1 reference

Adaptation in cyclic AMP signalling processes: A central role for cyclic AMP phosphodiesterases

21 January 2018

1 reference

Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Phosphodiesterase 4 conformers: preparation of recombinant enzymes and assay for inhibitors

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NBT1059

1 reference

Dimensions Publication ID

29 June 2017

0 references

1 reference